Skip to content
Home/How we work/Partnerships/J&J Innovative Medicine participates in TransCelerate Biopharma to accelerate development of new medicines

J&J Innovative Medicine participates in TransCelerate Biopharma to accelerate development of new medicines

Share Article
Share to
transcelerate_biopharma_logo.jpg

Janssen and nine other leading biopharmaceutical companies formed TransCelerate BioPharma Inc. (TransCelerate), a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating the delivery of innovative new therapies. Paul Stoffels, M.D., Chief Scientific Officer, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, sits on TransCelerate’s Board of Directors.

TransCelerate is focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges and further improving patient safety. The organization collaborates across the global R&D community to find, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of medicines.

TransCelerate continues to expand membership and launch new global initiatives that further advance efficiency in clinical trials and accelerate the development of new medicines.